Exscientia plc (LSE: EXAI) is a United Kingdom-based artificial intelligence-driven drug discovery company headquartered in Oxford, UK, that has pioneered the use of AI to design new small molecule therapeutics. Founded in 2012 by Professor Andrew Hopkins (former Professor of Computational Chemistry at Oxford University), Exscientia has developed a differentiated AI platform that combines generative AI, evolutionary design, and structural biology to accelerate the drug discovery process. The company has advanced multiple programs into clinical trials and established major pharmaceutical partnerships, positioning it as a leader in the emerging AI drug discovery space. While primarily focused on oncology and immunology, Exscientia has recently expanded into CNS disorders including Alzheimer's disease and Parkinson's disease[1].
| Attribute | Details |
|---|---|
| Headquarters | Oxford, United Kingdom |
| Founded | 2012 |
| IPO | 2021 (LSE: EXAI) |
| CEO | Andrew Hopkins |
| Market Cap | ~$300-500M (2024-2025) |
| Employees | ~300+ |
| Focus | AI drug discovery, small molecules |
| Year | Milestone |
|---|---|
| 2012 | Founded by Andrew Hopkins at Oxford |
| 2016 | First AI-designed candidate entered preclinical |
| 2019 | Partnership with Bristol Myers Squibb ($50M+) |
| 2020 | Partnership with Sanofi ($100M+) |
| 2021 | IPO on London Stock Exchange |
| 2022 | First AI-designed drug entered clinical trials |
| 2023 | Expanded into CNS/neurodegeneration |
| 2024 | Multiple Phase 1 programs ongoing |
Exscientia's platform integrates multiple AI and computational approaches:
Unlike traditional drug discovery, Exscientia's approach:
| Traditional | Exscientia AI Platform |
|---|---|
| 3-5 years to candidate | 12-18 months to candidate |
| Hundreds of compounds synthesized | Dozens of compounds synthesized |
| Linear optimization | Parallel multi-parameter optimization |
| Single target focus | Multi-target design |
Exscientia has advanced multiple AI-designed molecules into clinical development:
| Drug | Target | Stage | Indication | Notes |
|---|---|---|---|---|
| EXS21546 | A2A receptor antagonist | Phase 1/2 | Oncology | First AI-designed in clinic |
| EXS4318 | PKC-theta inhibitor | Phase 1 | Inflammation/Immunology | Partnership with BMS |
| GTAEXS-617 | CDK7 inhibitor | Phase 1 | Oncology | Internal program |
| EXS0262 | ERα degrader | Phase 1 | Breast cancer | Novel mechanism |
Exscientia has recently expanded into CNS disorders:
| Program | Target | Stage | Indication | Notes |
|---|---|---|---|---|
| EXS001 | TBA | Discovery | Alzheimer's disease | Tau or amyloid targeting |
| EXS002 | TBA | Discovery | Parkinson's disease | Alpha-synuclein or LRRK2 |
| EXS003 | TBA | Discovery | ALS | Multiple targets |
| Pain Program | NaV1.7 | Preclinical | Chronic pain | Ion channel targeting |
The company's AI capabilities are particularly valuable for neurodegeneration because:
| Program | Area | Stage | Partner |
|---|---|---|---|
| Oncology (multiple) | Various | Discovery/Preclinical | Bristol Myers Squibb |
| Immunology | Inflammation | Discovery | GSK |
| Cardiovascular | Various | Discovery | Internal |
Exscientia has established major pharmaceutical partnerships:
Exscientia distinguishes itself through several key differentiators:
The platform creates a closed loop between:
The AI simultaneously optimizes:
| Metric | Value |
|---|---|
| Stock Exchange | London Stock Exchange |
| Ticker | EXAI |
| IPO | 2021 |
| Market Cap | ~$300-500M |
| Cash Position | Sufficient through 2025+ |
| Partnership Revenue | $150M+ |
Exscientia competes with several AI drug discovery companies:
| Company | Focus | Status |
|---|---|---|
| Recursion | AI + biology platform | Public |
| Insilico Medicine | AI drug discovery | Private |
| Atomwise | AI molecular screening | Private |
| Schrödinger | Computational chemistry | Public |
| BenevolentAI | AI platform | Private |
Exscientia's entry into neurodegeneration is significant for several reasons:
The company can apply its AI platform to:
Opportunities include:
Chronic pain is a significant unmet need: